Becton, Dickinson faces a rare alignment of cautious signals this week. The put/call ratio hit its highest level in two weeks on the same day the stock dropped nearly 3%. Earnings land today.
The PCR jumped to 0.61 on April 29 — up sharply from a 20-day mean of 0.42. That's a z-score of 2.43, meaning the defensive positioning is statistically extreme relative to recent history. For context, BDX's PCR has traded below 0.40 for most of the past six weeks. The sudden shift to put-heavy flow stands out.
The stock fell 2.8% on April 29. It is down 6.6% over the past week and 6.0% over the past month. At $145.31, analysts' lowest recent target — Goldman Sachs at $167 — sits 15% above the current price.
Analyst sentiment has tilted negative since February. Every major firm that updated its target lowered it. Piper Sandler cut to $159 on April 17. Goldman Sachs reinstated at Neutral with a $167 target on April 10. Argus cut its target from $230 to $180 in March. The consensus sits at Hold, with 5 buys versus 9 holds.
The pattern is consistent: no upgrades, no raised targets, only reductions. The lowest current target in the snapshot ($159 from Piper Sandler) is still 9.4% above Tuesday's close — which captures just how far the stock has fallen.
BDX reports this morning (April 30, 12:00 UTC). The earnings history is sobering. The February 2026 print triggered an 18.3% single-day drop. The prior print in late 2025 saw a 14.5% five-day loss.
That February collapse also drove a spike in short interest — SI hit nearly 11.9M shares in mid-March, more than double current levels. Since then, shorts have unwound aggressively. SI now stands at 6.2M shares, or 2.17% of free float, down 42% over the past month. The borrow market remains extremely loose, with availability in the lending pool well above 1,000% — short sellers face essentially no supply constraint.
Cost to borrow climbed 25% over the past week to 0.53%, a modest rise but consistent with the broader defensive tone.
T. Rowe Price added 5.8M shares in Q1 — the largest institutional move in the snapshot — bringing its stake to 6.6% of shares outstanding. Vanguard added 4.2M shares. Both moves were Q1 filings and predate the recent selloff.
See the live data behind this article on ORTEX.
Open BDX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
